Nerivio® REN Wearable: A Drug-Free Therapy Where Meds Fall Short
There are millions of people who require a safe, effective, non-disruptive alternative that does not rely on pills or injections1,2. Nerivio is the only FDA-cleared Remote Electrical Neuromodulation (REN) wearable for patients aged 8+ that offers clinically proven preventive and acute migraine treatment—delivering safe, effective results without medication or systemic side effects.
Preventive & Acute
FDA Cleared
Clinically Proven
Safe & Discreet
Effective
Insurance covered
Proven Migraine Relief Based on Strong Scientific Evidence
Studies demonstrate that Nerivio provides safe and consistent migraine relief in the clinical and real-world setting. Data from our 22 peer reviewed publications include:
Achieved pain relief with Nerivio
Demonstrated sustained pain relief and pain freedom at 24 hours
Achieved higher relief than with medication
Reduction of 4 migraine days per month
Experienced ≥50% reduction in moderate to severe headache days
No device-related adverse events reported in the clinical study
Achieved pain relief with Nerivio
Achieved pain freedom with Nerivio
Did not use prescription medications
Why the Nerivio REN Wearable is a First Option for Migraine Care
Nerivio is designed to support adherence and fits seamlessly into patients’ daily lives. Incorporating Nerivio into early migraine management allows you to:
- Interrupt migraine progression before it becomes chronic
- Reduce medication reliance, especially for patients at risk for overuse headache
- Offer a safe and effective therapy for patients who can’t or won’t take medications
A Novel Mechanism of Action
Nerivio works by stimulating the Aδ and C fibers in the upper arm, triggering the Conditioned Pain Modulation (CPM) system. This activates the descending inhibitory pain pathway allowing for the release of serotonin and norepinephrine, globally impacting pain.
The Nerivio Patient Profile
Nerivio may be an optimal migraine management option for your patients, particularly for those in the following populations:
- Children and adolescents (ages 8 and up)
- Women of childbearing age
- People with comorbidities
- Veterans with migraine related challenges
- Individuals who need or prefer a drug-free solution
Guaranteed Coverage Pathway and Predictable Costs
Broad Coverage
Commercially and Medicaid-insured patients qualify for $0 full coverage.
Savings Program
For other plans, insured patients pay $49 for their first device and $89 for refills, under the Nerivio Savings Program.
Hassle-Free Access
Insurance verification and patient support are handled seamlessly to ensure timely access to treatment.
* Eligibility and coverage may vary by plan and state.
Doctors’ Recommendations
Watch Nerivio users share their migraine journeys and Nerivio’s impact on their lives. None have been compensated for sharing their Nerivio experience.
“With Nerivio, my patients have had a life-changing quality of life. Nerivio is not a want - it’s a need. This safe treatment for migraine is a vital breakthrough. It is my responsibility to let colleagues and patients know about this important therapy.”
“A large study of many patients over a lengthy period of time and multiple treatments, reinforces that REN [Nerivio] provides a safe, efficacious and stable treatment for acute migraine, both as a standalone and as an adjunct therapy."
“Chronic migraine patients experience more frequent and severe attacks than episodic migraine patients. Non-pharmacological interventions such as REN [Nerivio] help meet this need by providing a drug free treatment option.”
“Research shows this [REN, Nerivio] to be comparable with triptans. Pain relief at 2 hours was 67%, which is better than with many triptans.”
Sources
- 1. Yarnitsky D, Dodick DW, Grosberg BM, et al. Remote electrical neuromodulation (REN) for the acute treatment of migraine: a double-blind, randomized, placebo-controlled, multicenter trial. Headache. 2019;59(8):1240-1252. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963204/